GSK acquires Aiolos Bio for $1.4bn to boost respiratory portfolio
GSK’s acquisition, which comes amid other big money moves in the pharma industry, aims to broaden its asthma drug range.
Explore our marketing solutions
Genomics has been identified as the top emerging pharmaceutical industry trend for 2024, with its growth attributed to the increasing prevalence of chronic diseases, plummeting DNA sequencing costs, and increasing funding for genomics. Despite an optimistic outlook for 2024, the industry growth is predicted to be below 2022 levels primarily due to geopolitical conflicts, inflation, and drug pricing pressures.
